GSE229674 FRA1 knockdown NCI-H1975 1 v 0 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE229674_FRA1 knockdown_NCI-H1975_1_v_0_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE229674_FRA1 knockdown_NCI-H1975_1_v_0_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE229674_FRA1 knockdown_NCI-H1975_1_v_0_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE229674_FRA1 knockdown_NCI-H1975_1_v_0_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

C-X-C motif chemokine ligand 8

Gene

clusterin

Gene

interferon alpha inducible protein 27

Gene

argininosuccinate synthase 1

Gene

serpin family A member 1

Gene

paternally expressed 10

Gene

carbonic anhydrase 12

Gene

3-hydroxy-3-methylglutaryl-CoA synthase 1

Gene

interferon alpha inducible protein 6

Gene

ChaC glutathione specific gamma-glutamylcyclotransferase 1

  • Gene

    C-X-C motif chemokine ligand 8



  • Gene

    interferon alpha inducible protein 27


  • Gene

    argininosuccinate synthase 1


  • Gene

    serpin family A member 1


  • Gene

    paternally expressed 10


  • Gene

    carbonic anhydrase 12


  • Gene

    3-hydroxy-3-methylglutaryl-CoA synthase 1


  • Gene

    interferon alpha inducible protein 6


  • Gene

    ChaC glutathione specific gamma-glutamylcyclotransferase 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.